The case for & against
Bull & Bear analysis
10X Genomics, Inc. (NASDAQ: TXG) is a leading player in the life sciences sector, specializing in advanced genomic technologies that facilitate single-cell and spatial biology research. The company addresses significant challenges in biology and medicine with its innovative platforms, notably the Chromium and Atera systems. Positioned strategically within high-growth markets - particularly single-cell genomics and AI-driven research applications - 10X Genomics leverages its technological edge to enhance research capabilities in the biopharmaceutical and academic domains, redefining biological exploration at single-cell resolution.
Bull says
- ↑Q1’26 revenue $151M (+9% YoY); consumables up 13% YoY
- ↑Gross margin rose to 70% from 68% YoY, reflecting pricing power
- ↑Atera platform launch expected to expand spatial biology market share
- ↑Cash balance of $540M provides runway for R&D and operations
- ↑Positive analyst revisions and high-quality fundamentals signal upside
Bear says
- ↓Shares trading at ~$39 vs fair value ~$20, implying 94% overvaluation
- ↓Instrument revenue declined 24% YoY as customers delay CapEx
- ↓Negative earnings yield indicates weak return potential for investors
- ↓High volatility and 34% rise in short interest may pressure shares
- ↓Strong interest-rate sensitivity could further weigh on valuation
Investment themes with TXG
Companies that recently went public
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- I feel good about single-cell and kind of how it's proceeding. Again, still early time in the launch, but all in all, like really, really strong trajectory.
- Revenue for the first quarter was $151 million, representing 9% growth over Q1 2025, when excluding the non-recurring settlement revenue in the prior year period.
- double-digit growth in consumable reaction volumes, driven by Flex APEX. As we have expected, and as we have been seeing over the past several quarters, our new products with more accessible pricing have been unlocking new ways of single-cell demand.
Bear points
- I'd be remiss if I didn't say it's still fairly constrained.
- Total instrument revenue declined 24%, with chromium instrument revenue down 12%, and spatial instrument revenue down 32.
- We expect second quarter revenue to step down sequentially from Q1, reflecting lower spatial sales as customers wait for Atera to start shipping. We anticipate the third quarter to be broadly similar to the second quarter.